InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

- Current share price for TLX : $15.170

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,155 ANMI Transaction - Market Briefing 26 Nov 2018 8:30AM $0.700 $15.170 risen by 2,067.14%
$5,155 Telix Acquires Advanced Nuclear Medicine Ingredients SA 26 Nov 2018 8:30AM $0.700 $15.170 risen by 2,067.14%
$5,155 Quarterly Program Update 31 Oct 2018 8:23AM $0.865 $15.170 risen by 1,653.76%
$5,155 Appendix 4C - September Quarter 31 Oct 2018 8:13AM $0.865 $15.170 risen by 1,653.76%
$5,155 Telix Commences ZIRCON Phase III Renal Cancer Imaging Trial 23 Oct 2018 8:32AM $0.930 $15.170 risen by 1,531.18%
$5,155 Telix Receives Approval to Commence Glioblastoma Trial 18 Oct 2018 8:57AM $0.810 $15.170 risen by 1,772.84%
$5,155 RTM to Manufacture Kidney Imaging Program in Europe 17 Oct 2018 8:30AM $0.785 $15.170 risen by 1,832.48%
$5,155 Seibersdorf Laboratories Appointed for Glioblastoma Program 16 Oct 2018 8:29AM $0.740 $15.170 risen by 1,950%
$5,155 Interim Analysis of ZIR-DOSE Study Shows Improved Dosimetry 15 Oct 2018 8:34AM $0.715 $15.170 risen by 2,021.68%
$5,155 Telix and ANMI Expand PSMA Imaging Partnership 15 Oct 2018 8:28AM $0.715 $15.170 risen by 2,021.68%
$5,155 Cyclotek Manufacturing Partnership for Kidney Cancer Imaging 15 Oct 2018 8:28AM $0.715 $15.170 risen by 2,021.68%
$5,155 Strategic Collaboration Agreement with GenesisCare 10 Oct 2018 8:27AM $0.770 $15.170 risen by 1,870.13%
$5,155 Illumet Commercial Update 4 Oct 2018 10:47AM $0.838 $15.170 risen by 1,711.34%
$5,155 Agreement with Cardinal Health for Prostate Cancer Imaging 3 Oct 2018 8:27AM $0.820 $15.170 risen by 1,750%
$5,155 Ceasing to be a substantial holder 14 Sep 2018 4:54PM $0.830 $15.170 risen by 1,727.71%
$5,155 Appendix 3Y change of director's interests - Jann Skinner 14 Sep 2018 11:53AM $0.830 $15.170 risen by 1,727.71%
$5,155 Atlab Investor Conference Call - link to audio recording 14 Sep 2018 8:22AM $0.825 $15.170 risen by 1,738.79%
$5,155 Appendix 3B - issue of consideration shares and warrants 11 Sep 2018 1:35PM $0.850 $15.170 risen by 1,684.71%
$5,155 Section 708A(5)(e) Notice - Cleansing Notice 11 Sep 2018 1:33PM $0.850 $15.170 risen by 1,684.71%
$5,155 Atlab Transaction - Conference Call 11 Sep 2018 8:57AM $0.870 $15.170 risen by 1,643.68%
$5,155 Atlab Transaction - Market Briefing 11 Sep 2018 8:56AM $0.870 $15.170 risen by 1,643.68%
$5,155 Telix completes acquisition of Atlab Pharma 11 Sep 2018 8:56AM $0.870 $15.170 risen by 1,643.68%
$5,155 Trading Halt 10 Sep 2018 9:20AM $0.870 $15.170 risen by 1,643.68%
$5,155 TLX receives ethics approval to commence Glioblastoma Study 4 Sep 2018 9:18AM $0.925 $15.170 risen by 1,540%
$5,155 Policy- Compassionate Use Access to Investigational Medicine 31 Aug 2018 8:06AM $0.880 $15.170 risen by 1,623.86%

851 - 875 of 946 results

Page 35 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.